{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T05:45:09Z","timestamp":1772430309384,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,26]]},"DOI":"10.7759\/cureus.74489","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T12:37:41Z","timestamp":1732624661000},"source":"Crossref","is-referenced-by-count":3,"title":["A Retrospective Analysis of Demographics, Clinical Features, and Treatment Patterns in Sickle Cell Disease Patients at a Tertiary Healthcare Centre of North East India"],"prefix":"10.7759","author":[{"given":"Anupam","family":"Dutta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taniya S","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amlin","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Papori","family":"Gogoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510865","article-title":"Sickle cell disease","volume":"376","author":"Piel FB","year":"2017","unstructured":"Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017, 376:1561-73. 10.1056\/NEJMra1510865","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant M","year":"2010","unstructured":"Sant M, Allemani C, Tereanu C, et al.. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010, 116:3724-34. 10.1182\/blood-2010-05-282632","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/ijph.IJPH_964_20","article-title":"Community-based approach to prevention and control of noncommunicable diseases in the tribal population of India","volume":"65","author":"Nongkynrih B","year":"2021","unstructured":"Nongkynrih B, Patro BK, Pandav CS. Community-based approach to prevention and control of noncommunicable diseases in the tribal population of India. Indian J Public Health. 2021, 65:227-232. 10.4103\/ijph.IJPH_964_20","journal-title":"Indian J Public Health"},{"key":"ref4","unstructured":"National Health Mission, India. National Sickle Cell Anemia Elimination Mission. (2023). Accessed. 15 October 2023: https:\/\/sickle.nhm.gov.in."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4103\/0971-5916.178582","article-title":"Sickle cell disease in India: a perspective","volume":"143","author":"Serjeant GR","year":"2016","unstructured":"Serjeant GR, Ghosh K, Patel J. Sickle cell disease in India: a perspective. Indian J Med Res. 2016, 143:21-4. 10.4103\/0971-5916.178582","journal-title":"Indian J Med Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001142","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults","volume":"4","author":"DeBaun MR","year":"2020","unstructured":"DeBaun MR, Jordan LC, King AA, et al.. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv. 2020, 4:1554-88. 10.1182\/bloodadvances.2019001142","journal-title":"Blood Adv"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3758","article-title":"Survival of children with sickle cell disease","volume":"103","author":"Quinn CT","year":"2004","unstructured":"Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood. 2004, 103:4023-7. 10.1182\/blood-2003-11-3758","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a011817","article-title":"Current management of sickle cell anemia","volume":"3","author":"McGann PT","year":"2013","unstructured":"McGann PT, Nero AC, Ware RE. Current management of sickle cell anemia. Cold Spring Harb Perspect Med. 2013, 3:10.1101\/cshperspect.a011817","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref9","article-title":"Management of sickle cell disease: recommendations from the 2014 Expert Panel Report","volume":"92","author":"Yawn BP","year":"2015","unstructured":"Yawn BP, John-Sowah J. Management of sickle cell disease: recommendations from the 2014 Expert Panel Report. Am Fam Physician. 2015, 92:1069-76.","journal-title":"Am Fam Physician"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100643","article-title":"The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma","volume":"41","author":"Paner A","year":"2020","unstructured":"Paner A, Patel P, Dhakal B. The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma. Blood Rev. 2020, 41:100643. 10.1016\/j.blre.2019.100643","journal-title":"Blood Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24198","article-title":"Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial","volume":"90","author":"Hankins JS","year":"2015","unstructured":"Hankins JS, McCarville MB, Rankine-Mullings A, et al.. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. Am J Hematol. 2015, 90:1099-105. 10.1002\/ajh.24198","journal-title":"Am J Hematol"},{"key":"ref12","article-title":"Guidelines for the management of transfusion-dependent thalassemia (TDTNicosia: Thalassaemia International Federation","author":"Cappellini MD","year":"2014","unstructured":"Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V. Guidelines for the management of transfusion-dependent thalassemia (TDTNicosia: Thalassaemia International Federation. Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V (ed): Thalassaemia International Federation, Cyprus; 2014."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.08.009","article-title":"Future perspectives","volume":"34","author":"Dispenzieri A","year":"2020","unstructured":"Dispenzieri A, Merlini G. Future perspectives. Hematol Oncol Clin North Am. 2020, 34:1205-14. 10.1016\/j.hoc.2020.08.009","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30193-9","article-title":"Sickle cell disease","volume":"390","author":"Ware RE","year":"2017","unstructured":"Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017, 390:311-23. 10.1016\/S0140-6736(17)30193-9","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001484","article-title":"Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions","volume":"10","author":"Piel FB","year":"2013","unstructured":"Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions. PLoS Med. 2013, 10:e1001484. 10.1371\/journal.pmed.1001484","journal-title":"PLoS Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2005.1.51","article-title":"Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia","author":"Gladwin MT","year":"2005","unstructured":"Gladwin MT, Kato GJ. Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2005, 51-7. 10.1182\/asheducation-2005.1.51","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members","volume":"312","author":"Yawn BP","year":"2014","unstructured":"Yawn BP, Buchanan GR, Afenyi-Annan AN, et al.. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014, 312:1033-48. 10.1001\/jama.2014.10517","journal-title":"JAMA"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)","volume":"377","author":"Wang WC","year":"2011","unstructured":"Wang WC, Ware RE, Miller ST, et al.. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011, 377:1663-72. 10.1016\/S0140-6736(11)60355-3","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30133-0","article-title":"Sickle cell disease in Africa: an urgent need for longitudinal cohort studies","volume":"4","author":"Tluway F","year":"2017","unstructured":"Tluway F, Makani J. Sickle cell disease in Africa: an urgent need for longitudinal cohort studies. Lancet Haematol. 2017, 4:10.1016\/S2352-3026(17)30133-0","journal-title":"Lancet Haematol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.02.001","article-title":"A paradigm shift on beta-thalassaemia treatment: how will we manage this old disease with new therapies?","volume":"32","author":"Cappellini MD","year":"2018","unstructured":"Cappellini MD, Porter JB, Viprakasit V, Taher AT. A paradigm shift on beta-thalassaemia treatment: how will we manage this old disease with new therapies?. Blood Rev. 2018, 32:300-11. 10.1016\/j.blre.2018.02.001","journal-title":"Blood Rev"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-0843","article-title":"Changes in the epidemiology of thalassemia in North America: a new minority disease","volume":"116","author":"Vichinsky EP","year":"2005","unstructured":"Vichinsky EP, MacKlin EA, Waye JS, Lorey F, Olivieri NF. Changes in the epidemiology of thalassemia in North America: a new minority disease. Pediatrics. 2005, 116:e818-25. 10.1542\/peds.2005-0843","journal-title":"Pediatrics"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul H","year":"2021","unstructured":"Frangoul H, Altshuler D, Cappellini MD, et al.. CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N Engl J Med. 2021, 384:252-60. 10.1056\/NEJMoa2031054","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-012418-012838","article-title":"Pathophysiology of sickle cell disease","volume":"14","author":"Sundd P","year":"2019","unstructured":"Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol. 2019, 14:263-92. 10.1146\/annurev-pathmechdis-012418-012838","journal-title":"Annu Rev Pathol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/314797-a-retrospective-analysis-of-demographics-clinical-features-and-treatment-patterns-in-sickle-cell-disease-patients-at-a-tertiary-healthcare-centre-of-north-east-india","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T12:37:44Z","timestamp":1732624664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/314797-a-retrospective-analysis-of-demographics-clinical-features-and-treatment-patterns-in-sickle-cell-disease-patients-at-a-tertiary-healthcare-centre-of-north-east-india"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.74489","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,26]]}}}